Verici Logo

News

Material Transfer Agreement secured to assess CTOT-19 samples using Clarava™ and Tuteva™

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has entered into a Material Transfer Agreement (“MTA”) with the Icahn School of Medicine at Mount Sinai and Principal Investigator Dr. Peter Heeger, to allow access to samples from the CTOT-19 (Clinical Trials in Organ Transplant1) trial in an […]
Keep Reading

Final Results for the period ended 31 December 2020

April 14, 2021
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its inaugural audited results for the period ended 31 December 2020.   Strategic and Operational highlights Verici Dx was successfully admitted to AIM in November raising gross proceeds of c.$18.8m (£14.5m) The fundraising was significantly oversubscribed by institutional and other […]
Keep Reading

First clinical trial sites initiated in US

March 2, 2021
Three leading US centres first to collaborate with Verici in clinical validation trial for lead products Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has partnered with Lorenzo Gallon, MD, at Northwestern University Feinberg School of Medicine; Milagros Samaniego, MD, at Henry Ford Health System and […]
Keep Reading

Additional patent licence with Mount Sinai

January 11, 2021
Worldwide exclusive licence to liquid biopsy IP for predicting risk of fibrosis and chronic damage rejection Strengthens patent portfolio covering the entire kidney transplant diagnostic pathway   Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has expanded the scope of its licence agreement with the Icahn […]
Keep Reading

Appointment of Senior Director of Clinical Trial Operations Preparatory phase for validation trials complete

December 23, 2020
23 December 2020 Verici Dx plc (“Verici Dx” or the “Company”) Appointment of Senior Director of Clinical Trial Operations Preparatory phase for validation trials complete Site initiation of transplant centres on track for January 2021 Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has appointed Angela […]
Keep Reading

Admission to trading on AIM & First Day of Dealings

November 3, 2020
Capitalised terms used in this announcement shall, unless the context provides otherwise, have the same meaning as defined in the Admission Document. Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that admission to trading on AIM ("Admission") will take place and dealings will commence at 8.00 a.m. today […]
Keep Reading

Successful Restricted Offer Update on Fundraising and Admission

October 30, 2020
Capitalised terms in this announcement carry the same definitions as in prior announcements in relation to the Fundraising.   Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant, announces the result of the Restricted Offer made to its shareholders, who returned a valid application form to subscribe for Verici Dx Ordinary Shares […]
Keep Reading

Intention to admit to trading on AIM Proposed placing, subscription and a Restricted Offer

October 13, 2020
Verici Dx plc announces that it intends to apply to have its issued share capital, as enlarged by a proposed placing, subscription and a Restricted Offer, admitted to trading on AIM in due course.
Keep Reading

Verici Dx completes the Board of Directors with the appointment of Sir Ian Carruthers OBE

October 1, 2020
Sir Ian’s extensive and high level experience with NHS compliments the current Board’s experience with both US and UK healthcare environments NEW YORK, (September, 2020) — Verici Dx Plc (Verici), announced the appointment to the Board of Directors of Sir Ian Carruthers.  Sir Ian is experienced in the public, private and voluntary sectors and has […]
Keep Reading

Approval of distribution of shares in Verici Dx Limited and related party transaction

July 8, 2020
Download full announcement NEW YORK, 8 July, 2020 – Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it now proposes to distribute shares in its wholly-owned subsidiary, Verici Dx Limited (“Verici”). Following the approval […]
Keep Reading
1 2
© 2020 VericiDx
crossmenu